Author Login

Correspondence to Author: Jihad Mahmoud Kanbar, 

Tawam Hospital, Oncology Department, Al-Ain, UAE

Introduction: There are various types of plasma cell dyscrasias, ranging from mild (MGUS) to very aggressive (PCL). Primary PCL is a condition that develops from scratch, while leukemic transformation of underlying relapsing or Myeloma recalcitrant to treatment. The disease’s diagnostic standards have been thoroughly explained before [1]. The illness has an extremely bad prognosis and, even with vigorous therapy, typically progresses quickly and downward. The first proteasome inhibitor authorized for the treatment of multiple myeloma (MM) was boratezamib. According to recent findings, treating PCL upfront with this drug has shown positive results [2]. We discuss our PCL experience. There were five patients found to have PCL. While the other patients had secondary PCL, one patient had primary PCL.

Citation:

Jihad Mahmoud Kanbar. Tawam Hospital’s Experience with Plasma Cell Leukemia.. The Journal of Clinical Oncology 2024.